Leerink Partnrs Issues Positive Estimate for AVDL Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Leerink Partnrs increased their Q2 2025 EPS estimates for Avadel Pharmaceuticals in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.00 for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' FY2025 earnings at $0.10 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.35 EPS and FY2028 earnings at $1.70 EPS.

A number of other analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $12.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of Avadel Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $19.00 price target on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Avadel Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $19.43.

Avadel Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ AVDL traded down $0.14 during mid-day trading on Monday, reaching $8.76. The company had a trading volume of 291,469 shares, compared to its average volume of 1,224,123. Avadel Pharmaceuticals has a 52 week low of $6.38 and a 52 week high of $17.30. The business's 50-day moving average is $8.21 and its 200-day moving average is $9.39. The stock has a market cap of $845.99 million, a price-to-earnings ratio of -11.08 and a beta of 1.40.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The firm had revenue of $52.51 million for the quarter, compared to analysts' expectations of $50.57 million. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The business's revenue for the quarter was up 93.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) earnings per share.

Institutional Trading of Avadel Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its position in Avadel Pharmaceuticals by 45.8% in the 3rd quarter. Barclays PLC now owns 392,691 shares of the company's stock valued at $5,150,000 after acquiring an additional 123,430 shares in the last quarter. Krilogy Financial LLC grew its position in Avadel Pharmaceuticals by 53.6% in the 4th quarter. Krilogy Financial LLC now owns 26,362 shares of the company's stock valued at $277,000 after acquiring an additional 9,200 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Avadel Pharmaceuticals by 33.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 35,481 shares of the company's stock valued at $373,000 after acquiring an additional 8,815 shares in the last quarter. SG Americas Securities LLC grew its position in Avadel Pharmaceuticals by 274.6% in the 4th quarter. SG Americas Securities LLC now owns 46,767 shares of the company's stock valued at $492,000 after acquiring an additional 34,281 shares in the last quarter. Finally, Wealth Effects LLC grew its position in Avadel Pharmaceuticals by 4.9% in the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company's stock valued at $24,637,000 after acquiring an additional 110,359 shares in the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.